Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

<p>Study Schema</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Arathi Mohan (15561346) (author)
Tác giả khác:	Kent A. Griffith (15561349) (author), Fulei Wuchu (15561352) (author), David B. Zhen (15561355) (author), Chandan Kumar-Sinha (15130650) (author), Oxana Crysler (15561358) (author), David Hsiehchen (15561361) (author), Thomas Enzler (15561364) (author), Dominique Dippman (15561367) (author), Valerie Gunchick (15560621) (author), Abhinav Achreja (15561370) (author), Olamide Animasahun (15561373) (author), Srinadh Choppara (15561376) (author), Minal Nenwani (15561379) (author), Arul M. Chinnaiyan (15561382) (author), Deepak Nagrath (15561385) (author), Mark M. Zalupski (15561388) (author), Vaibhav Sahai (15560624) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Gastrointestinal Cancers Liver cancer Translational Research
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Bằng: Arathi Mohan (15561346)
Được phát hành: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Bằng: Tom Wei-Wu Chen (15053003)
Được phát hành: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Bằng: Tom Wei-Wu Chen (15053003)
Được phát hành: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Bằng: Tom Wei-Wu Chen (15053003)
Được phát hành: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Bằng: Tom Wei-Wu Chen (15053003)
Được phát hành: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Bằng: Tom Wei-Wu Chen (15053003)
Được phát hành: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Bằng: Yansong Lin (16374208)
Được phát hành: (2025)

Supplementary Figure S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Bằng: Benjamin K. Wilke (15055112)
Được phát hành: (2025)

Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Bằng: Benjamin K. Wilke (15055112)
Được phát hành: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Bằng: Amir T. Fathi (15313195)
Được phát hành: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Bằng: Amir T. Fathi (15313195)
Được phát hành: (2025)

Supplementary Tables 1-8 from Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER<sup>+</sup> Breast Cancer
Bằng: Gary N. Schwartz (16005870)
Được phát hành: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Bằng: Qingsheng Xu (17078830)
Được phát hành: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Bằng: Qingsheng Xu (17078830)
Được phát hành: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Bằng: John A. Ligon (15024477)
Được phát hành: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Bằng: Giuseppe Basile (15051269)
Được phát hành: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Bằng: Andrés Elía (15055031)
Được phát hành: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Bằng: Andrés Elía (15055031)
Được phát hành: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Bằng: Andrés Elía (15055031)
Được phát hành: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Bằng: Andrés Elía (15055031)
Được phát hành: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Bằng: Andrés Elía (15055031)
Được phát hành: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Bằng: Julio C. Chavez (15181310)
Được phát hành: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Bằng: Julio C. Chavez (15181310)
Được phát hành: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Bằng: Julio C. Chavez (15181310)
Được phát hành: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Bằng: Fabrice Barlesi (15045504)
Được phát hành: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
Bằng: Roger Li (17078665)
Được phát hành: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Bằng: Ulka N. Vaishampayan (15051039)
Được phát hành: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Bằng: Dwight H. Owen (15034782)
Được phát hành: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Bằng: Zachary Quinn (15052893)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3t6piq0b4v0nd7u7i8a7r94fkg